Response to Antiretroviral Therapy after a Single, Peripartum Dose of Nevirapine
This study analyzed the response to nevirapine-based antiretroviral treatment among 218 HIV-infected women in Botswana who had previously received either a single dose of nevirapine or placebo at the time of labor. After the single dose of nevirapine, 18.4% of recipients had treatment failure, as co...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2007-01, Vol.356 (2), p.135-147 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 147 |
|---|---|
| container_issue | 2 |
| container_start_page | 135 |
| container_title | The New England journal of medicine |
| container_volume | 356 |
| creator | Lockman, Shahin Shapiro, Roger L Smeaton, Laura M Wester, Carolyn Thior, Ibou Stevens, Lisa Chand, Fatima Makhema, Joseph Moffat, Claire Asmelash, Aida Ndase, Patrick Arimi, Peter van Widenfelt, Erik Mazhani, Loeto Novitsky, Vladimir Lagakos, Stephen Essex, Max |
| description | This study analyzed the response to nevirapine-based antiretroviral treatment among 218 HIV-infected women in Botswana who had previously received either a single dose of nevirapine or placebo at the time of labor. After the single dose of nevirapine, 18.4% of recipients had treatment failure, as compared with only 5.0% who received placebo. However, the risk of virologic failure did not seem to be increased when antiretroviral treatment was initiated 6 months or more, as compared with less than 6 months, after the peripartum dose of nevirapine.
This study analyzed the response to nevirapine-based antiretroviral treatment among 218 HIV-infected women in Botswana who had previously received either a single dose of nevirapine or placebo at the time of labor.
Nevirapine remains central to the prevention of mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) and to combination antiretroviral treatment throughout much of the developing world.
1
,
2
Nevirapine administered as one dose to the mother and one to the newborn reduces mother-to-child transmission of HIV-1 by 41 to 47%,
3
,
4
and well over 875,000 women and infants have received a single dose of nevirapine.
5
A single dose of nevirapine is the cornerstone of the regimen recommended by the World Health Organization (WHO) to prevent mother-to-child transmission among women without access to antiretroviral treatment and among those not meeting treatment . . . |
| doi_str_mv | 10.1056/NEJMoa062876 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68417130</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1193455311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c597t-9069f81619d18f52e0c46089abbac1890447df3415063f2e7a014fc2bb258023</originalsourceid><addsrcrecordid>eNqF0UtP3DAQAGALFcHyuPVcWVXpiYDfjyMCSkG8BHuPnOy4ZJXEqZ1U4t9jtCuBKiR8mcs3M54ZhL5SckSJVMe351c3wRHFjFYbaEYl54UQRH1BM0KYKYS2fBvtpLQk-VFht9A21YxKyekM3T9AGkKfAI8Bn_RjE2GM4V8TXYvnTxDd8IydHyFihx-b_k8Lh_geYjO4OE4dPgs5M3h8C68pQ9PDHtr0rk2wv467aP7rfH76u7i-u7g8Pbkuamn1WFiirDdUUbugxksGpBaKGOuqytXUWCKEXnguqCSKewba5a_7mlUVk4Ywvot-rsoOMfydII1l16Qa2tb1EKZUKiOoppx8ChnhVkihMvz-H1yGKfZ5hpIxbqnWTGd0uEJ1DClF8OUQm87F55KS8vUc5ftzZP5tXXOqOli84fX-MzhYA5dq1_ro-rpJb84IbjWX2f1Yua5LZQ_L7uN-L9kKm1E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223917727</pqid></control><display><type>article</type><title>Response to Antiretroviral Therapy after a Single, Peripartum Dose of Nevirapine</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><source>New England Journal of Medicine</source><creator>Lockman, Shahin ; Shapiro, Roger L ; Smeaton, Laura M ; Wester, Carolyn ; Thior, Ibou ; Stevens, Lisa ; Chand, Fatima ; Makhema, Joseph ; Moffat, Claire ; Asmelash, Aida ; Ndase, Patrick ; Arimi, Peter ; van Widenfelt, Erik ; Mazhani, Loeto ; Novitsky, Vladimir ; Lagakos, Stephen ; Essex, Max</creator><creatorcontrib>Lockman, Shahin ; Shapiro, Roger L ; Smeaton, Laura M ; Wester, Carolyn ; Thior, Ibou ; Stevens, Lisa ; Chand, Fatima ; Makhema, Joseph ; Moffat, Claire ; Asmelash, Aida ; Ndase, Patrick ; Arimi, Peter ; van Widenfelt, Erik ; Mazhani, Loeto ; Novitsky, Vladimir ; Lagakos, Stephen ; Essex, Max</creatorcontrib><description>This study analyzed the response to nevirapine-based antiretroviral treatment among 218 HIV-infected women in Botswana who had previously received either a single dose of nevirapine or placebo at the time of labor. After the single dose of nevirapine, 18.4% of recipients had treatment failure, as compared with only 5.0% who received placebo. However, the risk of virologic failure did not seem to be increased when antiretroviral treatment was initiated 6 months or more, as compared with less than 6 months, after the peripartum dose of nevirapine.
This study analyzed the response to nevirapine-based antiretroviral treatment among 218 HIV-infected women in Botswana who had previously received either a single dose of nevirapine or placebo at the time of labor.
Nevirapine remains central to the prevention of mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) and to combination antiretroviral treatment throughout much of the developing world.
1
,
2
Nevirapine administered as one dose to the mother and one to the newborn reduces mother-to-child transmission of HIV-1 by 41 to 47%,
3
,
4
and well over 875,000 women and infants have received a single dose of nevirapine.
5
A single dose of nevirapine is the cornerstone of the regimen recommended by the World Health Organization (WHO) to prevent mother-to-child transmission among women without access to antiretroviral treatment and among those not meeting treatment . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa062876</identifier><identifier>PMID: 17215531</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Adult ; Anti-Retroviral Agents - administration & dosage ; Anti-Retroviral Agents - therapeutic use ; Antiretroviral drugs ; Babies ; Biological and medical sciences ; Disease transmission ; Double-Blind Method ; Drug Resistance, Viral - genetics ; Drug Therapy, Combination ; Female ; General aspects ; Genotype ; HIV ; HIV Infections - drug therapy ; HIV Infections - transmission ; HIV-1 - genetics ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Human viral diseases ; Humans ; Infant, Newborn ; Infectious Disease Transmission, Vertical - prevention & control ; Infectious diseases ; Kaplan-Meier Estimate ; Labor, Obstetric ; Medical research ; Medical sciences ; Mutation ; Nevirapine - administration & dosage ; Pregnancy ; Pregnancy Complications, Infectious - drug therapy ; Pregnancy Trimester, Third ; Proportional Hazards Models ; Prospective Studies ; Risk Factors ; RNA, Viral - blood ; Treatment Failure ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral Load ; Zidovudine - therapeutic use</subject><ispartof>The New England journal of medicine, 2007-01, Vol.356 (2), p.135-147</ispartof><rights>Copyright © 2007 Massachusetts Medical Society. All rights reserved.</rights><rights>2007 INIST-CNRS</rights><rights>Copyright 2007 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c597t-9069f81619d18f52e0c46089abbac1890447df3415063f2e7a014fc2bb258023</citedby><cites>FETCH-LOGICAL-c597t-9069f81619d18f52e0c46089abbac1890447df3415063f2e7a014fc2bb258023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa062876$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa062876$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18439735$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17215531$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lockman, Shahin</creatorcontrib><creatorcontrib>Shapiro, Roger L</creatorcontrib><creatorcontrib>Smeaton, Laura M</creatorcontrib><creatorcontrib>Wester, Carolyn</creatorcontrib><creatorcontrib>Thior, Ibou</creatorcontrib><creatorcontrib>Stevens, Lisa</creatorcontrib><creatorcontrib>Chand, Fatima</creatorcontrib><creatorcontrib>Makhema, Joseph</creatorcontrib><creatorcontrib>Moffat, Claire</creatorcontrib><creatorcontrib>Asmelash, Aida</creatorcontrib><creatorcontrib>Ndase, Patrick</creatorcontrib><creatorcontrib>Arimi, Peter</creatorcontrib><creatorcontrib>van Widenfelt, Erik</creatorcontrib><creatorcontrib>Mazhani, Loeto</creatorcontrib><creatorcontrib>Novitsky, Vladimir</creatorcontrib><creatorcontrib>Lagakos, Stephen</creatorcontrib><creatorcontrib>Essex, Max</creatorcontrib><title>Response to Antiretroviral Therapy after a Single, Peripartum Dose of Nevirapine</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>This study analyzed the response to nevirapine-based antiretroviral treatment among 218 HIV-infected women in Botswana who had previously received either a single dose of nevirapine or placebo at the time of labor. After the single dose of nevirapine, 18.4% of recipients had treatment failure, as compared with only 5.0% who received placebo. However, the risk of virologic failure did not seem to be increased when antiretroviral treatment was initiated 6 months or more, as compared with less than 6 months, after the peripartum dose of nevirapine.
This study analyzed the response to nevirapine-based antiretroviral treatment among 218 HIV-infected women in Botswana who had previously received either a single dose of nevirapine or placebo at the time of labor.
Nevirapine remains central to the prevention of mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) and to combination antiretroviral treatment throughout much of the developing world.
1
,
2
Nevirapine administered as one dose to the mother and one to the newborn reduces mother-to-child transmission of HIV-1 by 41 to 47%,
3
,
4
and well over 875,000 women and infants have received a single dose of nevirapine.
5
A single dose of nevirapine is the cornerstone of the regimen recommended by the World Health Organization (WHO) to prevent mother-to-child transmission among women without access to antiretroviral treatment and among those not meeting treatment . . .</description><subject>Adult</subject><subject>Anti-Retroviral Agents - administration & dosage</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Antiretroviral drugs</subject><subject>Babies</subject><subject>Biological and medical sciences</subject><subject>Disease transmission</subject><subject>Double-Blind Method</subject><subject>Drug Resistance, Viral - genetics</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>General aspects</subject><subject>Genotype</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - transmission</subject><subject>HIV-1 - genetics</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Infectious Disease Transmission, Vertical - prevention & control</subject><subject>Infectious diseases</subject><subject>Kaplan-Meier Estimate</subject><subject>Labor, Obstetric</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Mutation</subject><subject>Nevirapine - administration & dosage</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - drug therapy</subject><subject>Pregnancy Trimester, Third</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>RNA, Viral - blood</subject><subject>Treatment Failure</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral Load</subject><subject>Zidovudine - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0UtP3DAQAGALFcHyuPVcWVXpiYDfjyMCSkG8BHuPnOy4ZJXEqZ1U4t9jtCuBKiR8mcs3M54ZhL5SckSJVMe351c3wRHFjFYbaEYl54UQRH1BM0KYKYS2fBvtpLQk-VFht9A21YxKyekM3T9AGkKfAI8Bn_RjE2GM4V8TXYvnTxDd8IydHyFihx-b_k8Lh_geYjO4OE4dPgs5M3h8C68pQ9PDHtr0rk2wv467aP7rfH76u7i-u7g8Pbkuamn1WFiirDdUUbugxksGpBaKGOuqytXUWCKEXnguqCSKewba5a_7mlUVk4Ywvot-rsoOMfydII1l16Qa2tb1EKZUKiOoppx8ChnhVkihMvz-H1yGKfZ5hpIxbqnWTGd0uEJ1DClF8OUQm87F55KS8vUc5ftzZP5tXXOqOli84fX-MzhYA5dq1_ro-rpJb84IbjWX2f1Yua5LZQ_L7uN-L9kKm1E</recordid><startdate>20070111</startdate><enddate>20070111</enddate><creator>Lockman, Shahin</creator><creator>Shapiro, Roger L</creator><creator>Smeaton, Laura M</creator><creator>Wester, Carolyn</creator><creator>Thior, Ibou</creator><creator>Stevens, Lisa</creator><creator>Chand, Fatima</creator><creator>Makhema, Joseph</creator><creator>Moffat, Claire</creator><creator>Asmelash, Aida</creator><creator>Ndase, Patrick</creator><creator>Arimi, Peter</creator><creator>van Widenfelt, Erik</creator><creator>Mazhani, Loeto</creator><creator>Novitsky, Vladimir</creator><creator>Lagakos, Stephen</creator><creator>Essex, Max</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20070111</creationdate><title>Response to Antiretroviral Therapy after a Single, Peripartum Dose of Nevirapine</title><author>Lockman, Shahin ; Shapiro, Roger L ; Smeaton, Laura M ; Wester, Carolyn ; Thior, Ibou ; Stevens, Lisa ; Chand, Fatima ; Makhema, Joseph ; Moffat, Claire ; Asmelash, Aida ; Ndase, Patrick ; Arimi, Peter ; van Widenfelt, Erik ; Mazhani, Loeto ; Novitsky, Vladimir ; Lagakos, Stephen ; Essex, Max</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c597t-9069f81619d18f52e0c46089abbac1890447df3415063f2e7a014fc2bb258023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Anti-Retroviral Agents - administration & dosage</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Antiretroviral drugs</topic><topic>Babies</topic><topic>Biological and medical sciences</topic><topic>Disease transmission</topic><topic>Double-Blind Method</topic><topic>Drug Resistance, Viral - genetics</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>General aspects</topic><topic>Genotype</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - transmission</topic><topic>HIV-1 - genetics</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Infectious Disease Transmission, Vertical - prevention & control</topic><topic>Infectious diseases</topic><topic>Kaplan-Meier Estimate</topic><topic>Labor, Obstetric</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Mutation</topic><topic>Nevirapine - administration & dosage</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - drug therapy</topic><topic>Pregnancy Trimester, Third</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>RNA, Viral - blood</topic><topic>Treatment Failure</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral Load</topic><topic>Zidovudine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lockman, Shahin</creatorcontrib><creatorcontrib>Shapiro, Roger L</creatorcontrib><creatorcontrib>Smeaton, Laura M</creatorcontrib><creatorcontrib>Wester, Carolyn</creatorcontrib><creatorcontrib>Thior, Ibou</creatorcontrib><creatorcontrib>Stevens, Lisa</creatorcontrib><creatorcontrib>Chand, Fatima</creatorcontrib><creatorcontrib>Makhema, Joseph</creatorcontrib><creatorcontrib>Moffat, Claire</creatorcontrib><creatorcontrib>Asmelash, Aida</creatorcontrib><creatorcontrib>Ndase, Patrick</creatorcontrib><creatorcontrib>Arimi, Peter</creatorcontrib><creatorcontrib>van Widenfelt, Erik</creatorcontrib><creatorcontrib>Mazhani, Loeto</creatorcontrib><creatorcontrib>Novitsky, Vladimir</creatorcontrib><creatorcontrib>Lagakos, Stephen</creatorcontrib><creatorcontrib>Essex, Max</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>Biological Sciences</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest_Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lockman, Shahin</au><au>Shapiro, Roger L</au><au>Smeaton, Laura M</au><au>Wester, Carolyn</au><au>Thior, Ibou</au><au>Stevens, Lisa</au><au>Chand, Fatima</au><au>Makhema, Joseph</au><au>Moffat, Claire</au><au>Asmelash, Aida</au><au>Ndase, Patrick</au><au>Arimi, Peter</au><au>van Widenfelt, Erik</au><au>Mazhani, Loeto</au><au>Novitsky, Vladimir</au><au>Lagakos, Stephen</au><au>Essex, Max</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response to Antiretroviral Therapy after a Single, Peripartum Dose of Nevirapine</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2007-01-11</date><risdate>2007</risdate><volume>356</volume><issue>2</issue><spage>135</spage><epage>147</epage><pages>135-147</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>This study analyzed the response to nevirapine-based antiretroviral treatment among 218 HIV-infected women in Botswana who had previously received either a single dose of nevirapine or placebo at the time of labor. After the single dose of nevirapine, 18.4% of recipients had treatment failure, as compared with only 5.0% who received placebo. However, the risk of virologic failure did not seem to be increased when antiretroviral treatment was initiated 6 months or more, as compared with less than 6 months, after the peripartum dose of nevirapine.
This study analyzed the response to nevirapine-based antiretroviral treatment among 218 HIV-infected women in Botswana who had previously received either a single dose of nevirapine or placebo at the time of labor.
Nevirapine remains central to the prevention of mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) and to combination antiretroviral treatment throughout much of the developing world.
1
,
2
Nevirapine administered as one dose to the mother and one to the newborn reduces mother-to-child transmission of HIV-1 by 41 to 47%,
3
,
4
and well over 875,000 women and infants have received a single dose of nevirapine.
5
A single dose of nevirapine is the cornerstone of the regimen recommended by the World Health Organization (WHO) to prevent mother-to-child transmission among women without access to antiretroviral treatment and among those not meeting treatment . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>17215531</pmid><doi>10.1056/NEJMoa062876</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2007-01, Vol.356 (2), p.135-147 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68417130 |
| source | MEDLINE; EZB Electronic Journals Library; New England Journal of Medicine |
| subjects | Adult Anti-Retroviral Agents - administration & dosage Anti-Retroviral Agents - therapeutic use Antiretroviral drugs Babies Biological and medical sciences Disease transmission Double-Blind Method Drug Resistance, Viral - genetics Drug Therapy, Combination Female General aspects Genotype HIV HIV Infections - drug therapy HIV Infections - transmission HIV-1 - genetics Human immunodeficiency virus Human immunodeficiency virus 1 Human viral diseases Humans Infant, Newborn Infectious Disease Transmission, Vertical - prevention & control Infectious diseases Kaplan-Meier Estimate Labor, Obstetric Medical research Medical sciences Mutation Nevirapine - administration & dosage Pregnancy Pregnancy Complications, Infectious - drug therapy Pregnancy Trimester, Third Proportional Hazards Models Prospective Studies Risk Factors RNA, Viral - blood Treatment Failure Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load Zidovudine - therapeutic use |
| title | Response to Antiretroviral Therapy after a Single, Peripartum Dose of Nevirapine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A04%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20to%20Antiretroviral%20Therapy%20after%20a%20Single,%20Peripartum%20Dose%20of%20Nevirapine&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Lockman,%20Shahin&rft.date=2007-01-11&rft.volume=356&rft.issue=2&rft.spage=135&rft.epage=147&rft.pages=135-147&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa062876&rft_dat=%3Cproquest_cross%3E1193455311%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223917727&rft_id=info:pmid/17215531&rfr_iscdi=true |